Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 74

1.

Diagnostic Leukapheresis Enables Reliable Transcriptomic Profiling of Single Circulating Tumor Cells to Characterize Inter-Cellular Heterogeneity in Terms of Endocrine Resistance.

Reinhardt F, Franken A, Meier-Stiegen F, Driemel C, Stoecklein NH, Fischer JC, Niederacher D, Ruckhaeberle E, Fehm T, Neubauer H.

Cancers (Basel). 2019 Jun 28;11(7). pii: E903. doi: 10.3390/cancers11070903.

2.

Circulating biomarkers for early detection and clinical management of colorectal cancer.

Marcuello M, Vymetalkova V, Neves RPL, Duran-Sanchon S, Vedeld HM, Tham E, van Dalum G, Flügen G, Garcia-Barberan V, Fijneman RJ, Castells A, Vodicka P, Lind GE, Stoecklein NH, Heitzer E, Gironella M.

Mol Aspects Med. 2019 Jun 14. pii: S0098-2997(19)30009-3. doi: 10.1016/j.mam.2019.06.002. [Epub ahead of print] Review.

3.

Detection of circulating tumor cells in colorectal cancer patients using the GILUPI CellCollector: results from a prospective, single-center study.

Dizdar L, Fluegen G, van Dalum G, Honisch E, Neves RP, Niederacher D, Neubauer H, Fehm T, Rehders A, Krieg A, Knoefel WT, Stoecklein NH.

Mol Oncol. 2019 Jul;13(7):1548-1558. doi: 10.1002/1878-0261.12507. Epub 2019 Jun 17.

4.

Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer.

Sumanasuriya S, Omlin A, Armstrong A, Attard G, Chi KN, Bevan CL, Shibakawa A, IJzerman MJ, De Laere B, Lolkema M, Lorente D, Luo J, Mehra N, Olmos D, Scher H, Soule H, Stoecklein NH, Terstappen LWMM, Waugh D, de Bono JS.

Eur Urol Oncol. 2018 Jun;1(2):151-159. doi: 10.1016/j.euo.2018.02.009. Epub 2018 May 15. Review.

5.

Label-Free Enrichment and Molecular Characterization of Viable Circulating Tumor Cells from Diagnostic Leukapheresis Products.

Franken A, Driemel C, Behrens B, Meier-Stiegen F, Endris V, Stenzinger A, Niederacher D, Fischer JC, Stoecklein NH, Ruckhaeberle E, Fehm T, Neubauer H.

Clin Chem. 2019 Apr;65(4):549-558. doi: 10.1373/clinchem.2018.296814. Epub 2019 Feb 8.

PMID:
30737205
6.

Diagnostic leukapheresis for CTC analysis in breast cancer patients: CTC frequency, clinical experiences and recommendations for standardized reporting.

Fehm TN, Meier-Stiegen F, Driemel C, Jäger B, Reinhardt F, Naskou J, Franken A, Neubauer H, Neves RPL, van Dalum G, Ruckhäberle E, Niederacher D, Rox JM, Fischer JC, Stoecklein NH.

Cytometry A. 2018 Dec;93(12):1213-1219. doi: 10.1002/cyto.a.23669.

PMID:
30551262
7.

Minimal Residual Disease in Head and Neck Cancer and Esophageal Cancer.

Sproll C, Fluegen G, Stoecklein NH.

Adv Exp Med Biol. 2018;1100:55-82. doi: 10.1007/978-3-319-97746-1_4. Review.

PMID:
30411260
8.

BRAFV600E mutation: A promising target in colorectal neuroendocrine carcinoma.

Dizdar L, Werner TA, Drusenheimer JC, Möhlendick B, Raba K, Boeck I, Anlauf M, Schott M, Göring W, Esposito I, Stoecklein NH, Knoefel WT, Krieg A.

Int J Cancer. 2019 Mar 15;144(6):1379-1390. doi: 10.1002/ijc.31828. Epub 2018 Oct 30.

PMID:
30144031
9.

Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis.

Lambros MB, Seed G, Sumanasuriya S, Gil V, Crespo M, Fontes M, Chandler R, Mehra N, Fowler G, Ebbs B, Flohr P, Miranda S, Yuan W, Mackay A, Ferreira A, Pereira R, Bertan C, Figueiredo I, Riisnaes R, Rodrigues DN, Sharp A, Goodall J, Boysen G, Carreira S, Bianchini D, Rescigno P, Zafeiriou Z, Hunt J, Moloney D, Hamilton L, Neves RP, Swennenhuis J, Andree K, Stoecklein NH, Terstappen LWMM, de Bono JS.

Clin Cancer Res. 2018 Nov 15;24(22):5635-5644. doi: 10.1158/1078-0432.CCR-18-0862. Epub 2018 Aug 9.

PMID:
30093450
10.

Toward a real liquid biopsy in metastatic breast and prostate cancer: Diagnostic LeukApheresis increases CTC yields in a European prospective multicenter study (CTCTrap).

Andree KC, Mentink A, Zeune LL, Terstappen LWMM, Stoecklein NH, Neves RP, Driemel C, Lampignano R, Yang L, Neubauer H, Fehm T, Fischer JC, Rossi E, Manicone M, Basso U, Marson P, Zamarchi R, Loriot Y, Lapierre V, Faugeroux V, Oulhen M, Farace F, Fowler G, Sousa Fontes M, Ebbs B, Lambros M, Crespo M, Flohr P, de Bono JS.

Int J Cancer. 2018 Nov 15;143(10):2584-2591. doi: 10.1002/ijc.31752. Epub 2018 Sep 19.

11.

ACGH detects distinct genomic alterations of primary intrahepatic cholangiocarcinomas and matched lymph node metastases and identifies a poor prognosis subclass.

Jansen R, Moehlendick B, Bartenhagen C, Tóth C, Lehwald N, Stoecklein NH, Knoefel WT, Lachenmayer A.

Sci Rep. 2018 Jul 13;8(1):10637. doi: 10.1038/s41598-018-28941-6.

12.

A streamlined workflow for single-cells genome-wide copy-number profiling by low-pass sequencing of LM-PCR whole-genome amplification products.

Ferrarini A, Forcato C, Buson G, Tononi P, Del Monaco V, Terracciano M, Bolognesi C, Fontana F, Medoro G, Neves R, Möhlendick B, Rihawi K, Ardizzoni A, Sumanasuriya S, Flohr P, Lambros M, de Bono J, Stoecklein NH, Manaresi N.

PLoS One. 2018 Mar 1;13(3):e0193689. doi: 10.1371/journal.pone.0193689. eCollection 2018.

13.

Clinicopathological and functional implications of the inhibitor of apoptosis proteins survivin and XIAP in esophageal cancer.

Dizdar L, Jünemann LM, Werner TA, Verde PE, Baldus SE, Stoecklein NH, Knoefel WT, Krieg A.

Oncol Lett. 2018 Mar;15(3):3779-3789. doi: 10.3892/ol.2018.7755. Epub 2018 Jan 9.

14.

Isolation of circulating tumor cells from pancreatic cancer by automated filtration.

Brychta N, Drosch M, Driemel C, Fischer JC, Neves RP, Esposito I, Knoefel W, Möhlendick B, Hille C, Stresemann A, Krahn T, Kassack MU, Stoecklein NH, von Ahsen O.

Oncotarget. 2017 Sep 16;8(49):86143-86156. doi: 10.18632/oncotarget.21026. eCollection 2017 Oct 17.

15.

Array comparative genomic hybridization of 18 pancreatic ductal adenocarcinomas and their autologous metastases.

Rausch V, Krieg A, Camps J, Behrens B, Beier M, Wangsa D, Heselmeyer-Haddad K, Baldus SE, Knoefel WT, Ried T, Stoecklein NH.

BMC Res Notes. 2017 Nov 6;10(1):560. doi: 10.1186/s13104-017-2886-0.

16.

Survivin and XIAP expression in distinct tumor compartments of surgically resected gastric cancer: XIAP as a prognostic marker in diffuse and mixed type adenocarcinomas.

Dizdar L, Tomczak M, Werner TA, Safi SA, Riemer JC, Verde PE, Stoecklein NH, Knoefel WT, Krieg A.

Oncol Lett. 2017 Dec;14(6):6847-6856. doi: 10.3892/ol.2017.6999. Epub 2017 Sep 19.

17.

Diagnostic pathology of early systemic cancer: ERBB2 gene amplification in single disseminated cancer cells determines patient survival in operable esophageal cancer.

Hoffmann M, Pasch S, Schamberger T, Maneck M, Möhlendick B, Schumacher S, Brockhoff G, Knoefel WT, Izbicki J, Polzer B, Stoecklein NH, Klein CA.

Int J Cancer. 2018 Feb 15;142(4):833-843. doi: 10.1002/ijc.31108. Epub 2017 Nov 30.

18.

Circulating Tumour Cell Release after Cement Augmentation of Vertebral Metastases.

Mohme M, Riethdorf S, Dreimann M, Werner S, Maire CL, Joosse SA, Bludau F, Mueller V, Neves RPL, Stoecklein NH, Lamszus K, Westphal M, Pantel K, Wikman H, Eicker SO.

Sci Rep. 2017 Aug 3;7(1):7196. doi: 10.1038/s41598-017-07649-z.

19.

Disseminated tumour cells with highly aberrant genomes are linked to poor prognosis in operable oesophageal adenocarcinoma.

Schumacher S, Bartenhagen C, Hoffmann M, Will D, Fischer JC, Baldus SE, Vay C, Fluegen G, Dizdar L, Vallböhmer D, Klein CA, Knoefel WT, Stoecklein NH, Möhlendick B.

Br J Cancer. 2017 Aug 22;117(5):725-733. doi: 10.1038/bjc.2017.233. Epub 2017 Jul 20.

20.

Immunohistochemical detection of lymph node-DTCs in patients with node-negative HNSCC.

Sproll C, Freund AK, Hassel A, Hölbling M, Aust V, Storb SH, Handschel J, Teichmann C, Depprich R, Behrens B, Neves RP, Kübler NR, Kaiser P, Baldus SE, Tóth C, Kaisers W, Stoecklein NH.

Int J Cancer. 2017 May 1;140(9):2112-2124. doi: 10.1002/ijc.30617. Epub 2017 Feb 8.

Supplemental Content

Loading ...
Support Center